Now Reading
Nucleus, an AI-Powered Genomics Company, Secures $32M in Funding
`

Nucleus, an AI-Powered Genomics Company, Secures $32M in Funding

Genomics Testing Nucleus
The company received funding from key players like Reddit founder Alexis Ohanian and Peter Thiel’s Founders Fund

Nucleus, the leader in clinical-grade DNA and health technology, has secured a $14 million Series A round, bringing its total funding to nearly $32 million. Backed by investors including Reddit founder Alexis Ohanian and Peter Thiel’s Founders Fund, Nucleus offers open access to clinical genetic testing.

The U.S. healthcare system expends nearly $4.5 trillion annually, but unrest around the industry is rampant.

“The consumer health industry is at a critical inflection point, and Nucleus is positioned to create the most consequential healthcare company of our generation,” Kian Sadeghi, CEO and founder of Nucleus told Athletech News. “In today’s broken system, consumers crave agency. Nucleus is giving them that power, with health insights starting at the genetic level.”

Nucleus focuses on preventative health, providing risk assessments for over 800 diseases, including cancers, heart disease, and Alzheimer’s.

“The next trillion-dollar business is going to be in consumer health,” said Alexis Ohanian, whose firm Seven Seven Six has invested over $10 million in Nucleus. “In today’s healthcare climate, there’s no one else on the market who has built a future-focused, patient-first solution of this caliber.”

The new funding follows Nucleus’s acquisition of Cambrean, an AI-driven health platform that converts data from wearables like Oura rings and Apple Watches into actionable health assessments.

See Also

“Consumer health startups have measured individual data points in isolation,” Sadeghi explained. “Nucleus is filling the gap by contextualizing each data point with DNA, telling the complete story of an individual’s health from the foundation.”

Nucleus also introduced several new features. AI Doctor is a natural language interface that enables users to query and monitor their genetic and biometric health data. Second Pharmacogenomics provides insights into how DNA variants affect responses to medications. Family Forecast provides screens for over 800 hereditary conditions. Lastly, the company has new partnerships with Bionic Health and Legacy.  

“Healthcare shouldn’t be reactive,” said Sadeghi. “It should be proactive. And that’s exactly what we’re building.”

Scroll To Top